NURVAQAY
Live / Registered — Registered (as of 10 Feb 2026)
What this means for you
Registered since 10 Feb 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99371409
- Registration number
- 8137357
- Mark type
- Stylized text
- Filed
- 03 Sept 2025
- Published for opposition
- 23 Dec 2025
- Registered
- 10 Feb 2026
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives
Owner
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 10 Feb 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 10 Feb 2026 — REGISTERED-PRINCIPAL REGISTER
- 23 Dec 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 23 Dec 2025 — PUBLISHED FOR OPPOSITION
- 17 Dec 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 25 Nov 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 20 Nov 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 20 Nov 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 20 Nov 2025 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
- 24 Oct 2025 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 24 Oct 2025 — LETTER OF SUSPENSION E-MAILED
- 24 Oct 2025 — SUSPENSION LETTER WRITTEN
- 24 Oct 2025 — ASSIGNED TO EXAMINER
- 03 Sept 2025 — APPLICATION FILING RECEIPT MAILED
- 03 Sept 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED